Phase Ib pancreatic cancer data demonstrate Halozyme hyaluronan thesis
This article was originally published in Scrip
Executive Summary
Progression-free survival (PFS) was twice as high and overall survival was three times as high for pancreatic cancer patients with high levels of tumor-associated hyaluronan (HA) who were treated with Halozyme Therapeutics's PEGPH20 (pegylated recombinant human hyaluronidase) plus gemcitabine than for patients whose tumors had low HA levels in a Phase Ib clinical trial.
You may also be interested in...
Halozyme's 2017 Includes PEGPH20 Milestones, New Partnership
Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.